In accordance with Article 13 of Law No. 104-12 on freedom of prices and competition and Article 10 of Decree No. 2-14-652 issued for its implementation, as amended and supplemented, the Competition Council makes available to the public the ‘summary of the operation’ below, containing the information provided by the parties.<\/p>\n
This information has been prepared by the notifying parties, who are solely responsible. Any inaccurate or distorted information contained therein does not in any way prejudge the Competition Council’s position on the planned operation.<\/p>\n
The publication of this press release does not attest to the completeness of the file provided for in Article 9 of Decree No. 2-14-652 issued for the implementation of Law No. 104-12 on freedom of prices and competition as amended and supplemented.<\/p>\n
Names of the companies and groups concerned:<\/strong><\/p>\n Founding companies:<\/strong><\/p>\n The joint venture:<\/strong><\/p>\n Nature of the operation:<\/strong><\/p>\n Economic sectors concerned:<\/strong><\/p>\n Deadline for interested third parties to submit their observations:<\/strong><\/p>\n NON-CONFIDENTIAL SUMMARY OF THE OPERATION PROVIDED BY THE PARTIES<\/strong><\/p>\n The Competition Council has received notification of an economic concentration operation concerning the establishment of the joint venture ‘Terafront Farmatech SL’ jointly by the companies ‘Laboratorios Farmac\u00e9uticos Rovi SA’, ‘Innvierte Econom\u00eda Sostenible SICC, SME, SA’ and ‘Insud Pharma SL’.<\/p>\n ‘Laboratorios Farmaceuticos Rovi SA’, <\/strong>parent company of the Rovi group, is a Spanish public limited company, headquartered in Madrid and listed on the stock exchange. It specializes in research, development, manufacturing, and marketing of small molecules and biological specialties.<\/p>\n ‘Innvierte Econom\u00eda Sostenible SICC, SME, SA’ <\/strong>is a Spanish public limited company, headquartered in Madrid. It specializes in venture capital investments in the technology sector.<\/p>\n ‘Insud Pharma SL’, Spanish parent company of the pharmaceutical group ‘Insud Pharma’, is a Spanish limited liability company, headquartered in Madrid. It is active in research, development, and innovation in the pharmaceutical sector.<\/p>\n ‘Terafront Farmatech SL’ is a Spanish limited liability joint venture dedicated to the development of advanced, innovative, or emerging drugs, therapies, or technologies in the healthcare field.<\/p>\n <\/p>\n Done in Rabat, on October 17, 2024.<\/p>\n","protected":false},"excerpt":{"rendered":" In accordance with Article 13 of Law No. 104-12 on freedom of prices and competition and Article 10 of Decree No. 2-14-652 issued for its implementation, as amended and supplemented, the Competition Council makes available to the public the ‘summary of the operation’ below, containing the information provided by the parties. This information has been prepared by the notifying parties, who are solely responsible. Any inaccurate or distorted information contained therein does not in any way prejudge the Competition Council’s position on the planned operation. The publication of this press release does not attest to the completeness of the file provided for in Article 9 of Decree No. 2-14-652 issued for the implementation of Law No. 104-12 on freedom of prices and competition as amended and supplemented. Names of the companies and groups concerned: Founding companies: The company ‘Laboratorios Farmaceuticos Rovi SA’; The company ‘Innvierte Economia Sostenible SICC, SME, SA’; The company ‘Insud Pharma SL’. The joint venture: ‘Terafront Farmatech SL’ Nature of the operation: Establishment of a joint venture. Economic sectors concerned: The Pharmaceutical production sector. Deadline for interested third parties to submit their observations: 10 days from the date of publication of this press release, i.e. October 31, 2024. NON-CONFIDENTIAL SUMMARY OF THE OPERATION PROVIDED BY THE PARTIES The Competition Council has received notification of an economic concentration operation concerning the establishment of the joint venture ‘Terafront Farmatech SL’ jointly by the companies ‘Laboratorios Farmac\u00e9uticos Rovi SA’, ‘Innvierte Econom\u00eda Sostenible SICC, SME, SA’ and ‘Insud Pharma SL’. ‘Laboratorios Farmaceuticos Rovi SA’, parent company of the Rovi group, is a Spanish public limited company, headquartered in Madrid and listed on the stock exchange. It specializes in research, development, manufacturing, and marketing of small molecules and biological specialties. ‘Innvierte Econom\u00eda Sostenible SICC, SME, SA’ is a Spanish public limited company, headquartered in Madrid. It specializes in venture capital investments in the technology sector. ‘Insud Pharma SL’, Spanish parent company of the pharmaceutical group ‘Insud Pharma’, is a Spanish limited liability company, headquartered in Madrid. It is active in research, development, and innovation in the pharmaceutical sector. ‘Terafront Farmatech SL’ is a Spanish limited liability joint venture dedicated to the development of advanced, innovative, or emerging drugs, therapies, or technologies in the healthcare field. Done in Rabat, on October 17, 2024.<\/p>\n","protected":false},"author":5,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[352],"tags":[],"class_list":["post-40545","post","type-post","status-publish","format-standard","hentry","category-press-releases"],"acf":[],"yoast_head":"\n\n
\n
\n
\n
\n